CJC-1295 Interactions: Alcohol, Caffeine, Food and Other Compounds

Interaction questions about CJC-1295 — a growth hormone-releasing hormone (GHRH) analogue — almost always run ahead of the evidence. The honest starting point is that the indexed literature contains no controlled human or animal trial that co-administered CJC-1295 with ethanol, caffeine, a defined meal, or a fasting window and measured the difference. That absence is not a hidden finding; it is simply what the record shows. This page describes the studies that do exist, states plainly where none exist, and labels mechanistic reasoning as reasoning rather than as evidence. Background on the molecule itself sits on the CJC-1295 overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision, medication, or supplement. Nothing here describes a protocol, a combination, or a timing strategy.

What the Interaction Literature Actually Contains

Three categories of published work bear on the question, and none of them is a direct interaction trial. First, review-level work on peptide therapeutics: a 2026 review in Frontiers in Aging surveyed mechanisms and applications of therapeutic peptides in gerontology, placing growth hormone axis peptides within a broader class whose behaviour depends on receptor pharmacology and clearance (PMID 42021992). Second, receptor-level work: a 2022 study in Talanta reported that cannabinoids show affinity interaction with the growth hormone secretagogue receptor, and researchers built an early-detection assay for cannabinoids in biological samples on that interaction (PMID 34736642). Third, analytical work: a 2012 methods paper described immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls (PMID 21871962).

Taken together, that citation set explains the pharmacological and analytical context in which interaction questions would have to be answered, but it does not answer them (PMID 42021992, PMID 21871962).

Alcohol and CJC-1295

What has been studied

No identified clinical trial, animal study, or case series administered CJC-1295 alongside ethanol and measured growth hormone output, IGF-1, sleep architecture, or adverse events. There is therefore no published effect size, no direction of effect, and no dose relationship to report.

Mechanistic reasoning (labeled as reasoning, not evidence)

Researchers who discuss this pairing reason from general endocrine physiology rather than from CJC-1295 data. The reasoning runs: GHRH analogues act on pituitary somatotrophs, the pulsatile release they influence is tightly linked to slow-wave sleep, and ethanol is known in the wider sleep literature to alter sleep architecture. From that chain, an expectation of interference is inferred, not demonstrated. The 2026 gerontology review framed peptide activity as receptor- and clearance-dependent, which is the same logic applied here, but the review did not test ethanol co-exposure (PMID 42021992). Any claim that alcohol "blocks" or "reduces" the response to CJC-1295 by a stated percentage would be an invented figure; no such figure exists in the verified literature.

Caffeine and CJC-1295

What has been studied

The same gap applies. No published study co-administered caffeine with CJC-1295, and no paper in the verified set reported a caffeine-related change in GHRH-analogue pharmacokinetics or pharmacodynamics.

Mechanistic reasoning (labeled as reasoning, not evidence)

Two mechanistic lines are typically raised in discussion. One concerns adenosine antagonism and its downstream effects on arousal and sleep latency, on the reasoning that anything disturbing slow-wave sleep could plausibly intersect with growth hormone pulsatility. The other concerns hepatic metabolism, which is largely irrelevant for a peptide: peptide hormones are handled by peptidase-mediated degradation and renal or receptor-mediated clearance rather than by the cytochrome P450 pathways that drive classic small-molecule drug interactions, a distinction the peptide-class literature emphasises (PMID 42021992). On that basis, researchers generally treat a caffeine-peptide metabolic interaction as mechanistically unlikely — but "unlikely on mechanism" is not the same as "tested and excluded."

Food, Fasting and Meal Timing

What has been studied

No verified trial compared CJC-1295 administration in a fed versus fasted state. Claims circulating about specific pre- or post-meal windows are not traceable to a published CJC-1295 study, and this page does not reproduce them.

Mechanistic reasoning (labeled as reasoning, not evidence)

The nutritional reasoning invoked is that circulating glucose, insulin, and free fatty acids modulate somatotroph responsiveness in classical endocrine physiology, so nutritional state is expected to be a variable in any GHRH-analogue study design. That is why well-designed pharmacodynamic studies of growth hormone axis peptides standardise feeding conditions — as a control for confounding, not as a demonstrated interaction. The gerontology review discussed peptide pharmacology in terms of the physiological context in which peptides act, which is the framework behind this reasoning (PMID 42021992).

Cannabinoids and the Growth Hormone Secretagogue Receptor

This is the one "other compound" question with a directly relevant published receptor finding, and it requires a precise reading. The 2022 Talanta study reported that cannabinoids interact by affinity with the growth hormone secretagogue receptor (GHS-R), and researchers exploited that binding to detect cannabinoids in biological samples at an early stage (PMID 34736642). Two caveats matter. First, GHS-R is the ghrelin receptor — the target of growth hormone secretagogues such as the GHRP family — and it is not the GHRH receptor that CJC-1295 is described as acting upon. Second, the study was an analytical detection study; it did not administer cannabinoids and a peptide together, and it did not measure growth hormone output, so it reported no clinical interaction (PMID 34736642). It establishes that a receptor in the growth hormone axis has binding partners outside the classical peptide ligands, which is a mechanistic observation, not an interaction result.

Commonly Asked Compound Pairings

The table below records what the verified literature contains for each frequently asked pairing. "No identified study" means exactly that: no trial in the verified set examined the combination, and no effect is claimed here in either direction.

Why Interaction Data Are Thin: The Measurement Problem

One under-discussed reason interaction studies are scarce is analytical. Quantifying peptide hormones in blood or urine is technically demanding: the 2012 Methods paper described immunoaffinity purification steps applied before liquid chromatography-mass spectrometry so that peptide hormones could be detected in doping control samples, with antibody-based capture used to isolate the target from the biological matrix (PMID 21871962). An interaction study requires measuring the peptide, its downstream markers, and the co-administered substance across a time course, in enough participants to separate signal from noise. Where those assays are laborious, the studies do not get done — which is a resource explanation for the gap, not evidence that no interaction exists (PMID 21871962).

Interactions and Adverse Events: What Studies Report

No verified study reported an adverse event arising specifically from combining CJC-1295 with alcohol, caffeine, food, or another named compound. There is no published case report of such a combination in the citation set, and therefore no frequency, severity, or causality assessment to summarise. Statements elsewhere that a particular pairing is "safe" or "dangerous" are not sourced to the studies cited here; the verified literature reported detection chemistry, sample purification methodology, and class-level peptide mechanisms rather than combination safety outcomes (PMID 34736642, PMID 21871962, PMID 42021992). Readers evaluating claims about combination risk should look for whether the source names a study, a population, and an outcome measure — and whether the peptide was actually co-administered with the second substance.

How Researchers Distinguish Evidence From Inference

A useful filter when reading interaction claims about GHRH analogues:

• Was the combination actually administered? Receptor-affinity work such as the GHS-R cannabinoid assay demonstrated binding in an analytical system, not co-administration in a living subject (PMID 34736642).
• Was an outcome measured? Detection and purification methodology answers "can we see it," not "what did it do" (PMID 21871962).
• Is the receptor the same one? GHS-R findings do not transfer automatically to GHRH-receptor pharmacology (PMID 34736642).
• Is the claim class-level or molecule-level? Review articles describe peptide classes broadly; they do not substitute for molecule-specific trials (PMID 42021992).

CJC-1295 is not an approved medicine in the United States and is encountered in research and analytical settings, which is part of why the peptide appears in doping-control methodology literature rather than in interaction pharmacology trials (PMID 21871962). Until controlled co-administration studies are published, the accurate description of every pairing on this page is the same: examined mechanistically, not tested directly.

References

• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026)
• Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor (Talanta, 2022)
• Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls (Methods, 2012)